Oncology Brothers: Practice-Changing Cancer Discussions cover image

Managing Side Effects of New Treatments for Small Cell Lung Cancer

Oncology Brothers: Practice-Changing Cancer Discussions

00:00

Lurbinectedin, Hematologic Risks, and Growth Factor Strategy

Discussion of the post‑ASCO 2025 treatment algorithm, expected hematologic toxicities with lurbinectedin, distinguishing liver injury patterns from IO, and practical use of trilaciclib versus G‑CSF in maintenance.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app